Abstract
Eli Lilly and Company is reporting positive results in a small trial of donanemab, an experimental antibody treatment for Alzheimer’s disease. The Phase 2 trial, which was placebo controlled and double blinded, followed 272 people for about 18 months. “It potentially is very exciting,” says David Holtzman, an Alzheimer’s disease expert at the Washington University School of Medicine, describing one of Lilly’s reported findings: a 32% drop in cognitive decline, as measured by one of many tests given to people who received the antibody. Holtzman says other experimental treatments haven’t delivered such a result. Like other antibodies for Alzheimer’s, donanemab targets clumps of protein in the brain called amyloid-β. But donanemab binds to a less prevalent section of the protein containing an altered amino acid called pyroglutamate. Nearly everyone who has Alzheimer’s has some pyroglutamate, says John Sims, Lilly’s senior medical director for neurodegeneration. According to Holtzman, when treatments like
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.